Begin main content

Long-Acting Insulin Analogues versus Human NPH Insulin for Adults with Type 2 Diabetes and Unresponsive to Non-insulin Therapies: Clinical Effectiveness, Cost-Effectiveness, and Guidelines

Last updated: May 3, 2019
Project Number: RB1331-000
Product Line: Rapid Response
Research Type: Drug
Report Type: Summary of Abstracts
Result type: Report

Question

  1. What is the comparative clinical effectiveness of long-acting insulin analogues versus human NPH insulin for the treatment of adults with type 2 diabetes who are not responding to non-insulin therapies alone?
  2. What is the comparative cost-effectiveness of long-acting insulin analogues versus human NPH insulin for the treatment of adults with type 2 diabetes who are not responding to non-insulin therapies alone?
  3. What are the evidence-based guidelines regarding the selection of a first-line insulin therapy for the treatment of adults with type 2 diabetes who are not responding to non-insulin therapies alone?

Key Message

Two evidence-based guidelines were identified regarding the selection of first-line insulin therapy for the treatment of adults with type 2 diabetes who are unresponsive to non-insulin therapies. No relevant studies pertaining to the comparative clinical effectiveness and cost-effectiveness of long-lasting insulin analogues versus human NPH insulin were identified.